-
Taysha Gene Therapies (TSHA) Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial
-
Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results
-
Taysha Gene Therapies (TSHA) Announces $150M Financing
-
Taysha Gene Therapies Announces $150 Million Private Placement Financing

